LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

ENANTA PHARMACEUTICALS INC

Fechado

SetorSaúde

13.66 -2.36

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.62

Máximo

14.54

Indicadores-chave

By Trading Economics

Rendimento

-1.2M

-13M

Vendas

-1.5M

17M

EPS

-0.451

Margem de lucro

-76.292

Funcionários

120

EBITDA

-958K

-8.6M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+42.25% upside

Dividendos

By Acuity

Próximos Ganhos

7 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-33M

389M

Abertura anterior

16.02

Fecho anterior

13.66

Sentimento de Notícias

By Acuity

97%

3%

322 / 342 Ranking em Healthcare

ENANTA PHARMACEUTICALS INC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Sobre ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
help-icon Live chat